Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Common Equity (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Common Equity for 9 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 83.42% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Oct 2025, up 83.42%, and an annual FY2025 reading of $1.9 million, up 80.76% over the prior year.
  • Common Equity was $1.9 million for Q4 2025 at VitaNova Life Sciences, up from $1.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.9 million in Q2 2025 and bottomed at -$174670.0 in Q2 2021.
  • Average Common Equity over 5 years is $498585.0, with a median of -$23675.5 recorded in 2021.
  • The sharpest move saw Common Equity plummeted 570.21% in 2023, then surged 1883.23% in 2024.
  • Year by year, Common Equity stood at -$17098.0 in 2021, then tumbled by 76.94% to -$30253.0 in 2022, then tumbled by 204.82% to -$92217.0 in 2023, then skyrocketed by 1222.22% to $1.0 million in 2024, then soared by 83.42% to $1.9 million in 2025.
  • Business Quant data shows Common Equity for YJGJ at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.